Nanoscope Therapeutics to Present at the 2023 American Society of Retina Specialists (ASRS) Annual Scientific Meeting

Nanoscope Therapeutics to Present at the 2023 American Society of Retina Specialists (ASRS) Annual Scientific Meeting

DALLAS, TX (July 21, 2023) — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation at the 2023 ASRS Annual Scientific Meeting taking place from July 28-August 1, 2023 in Seattle, Washington. The management team will be in attendance at the conference and accessible for meetings.

Details for the presentation are as follows:

Abstract Title: MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes from the Phase 2 STARLIGHT Trial

Paper Type: Late Breaking Presentation

Session Title: Hereditary Retinal Disease & Genetics Symposium

Session Date: Monday, July 31, 2023

Session Time: 4:30 PM PT

Presenter: Allen C. Ho, MD, FASRS, Professor of Ophthalmology at Thomas Jefferson University and Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service at Wills Eye Hospital

Dr. Ho will present the safety and efficacy results obtained from the Phase 2 STARLIGHT trial focusing on Stargardt disease. These outcomes will play a vital role in shaping the future clinical development of MCO-010 optogenetic therapy, aimed at restoring vision in patients with Stargardt macular degeneration and other retinal degenerative diseases.

About Nanoscope Therapeutics Inc.

Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also fully enrolled a Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

On July 21, 2023   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.